Company intelligence / Profile preview

ARIUS Research

Toronto, Ontario, Canada

Ownership: Private
Development stage: Preclinical

Overview

ARIUS developed a proprietary antibody discovery platform and built a pipeline of over 400–500 antibody candidates targeting cancer and other diseases. Several lead programs targeted cancer stem cell markers such as CD9 and CD44. The company was acquired by Roche in 2008 to access its FunctionFIRST™ screening platform for antibody therapeutics. No late-stage clinical results were reported prior to acquisition.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodies (mAbs)Antibody therapeutics
Industry: Biotech

Partnerships

Avid Bioservices (manufacturing agreement for anti-CD44 program)Multiple undisclosed biotech/drug development companies for partnerships/licensing

Beyond the preview

Go deeper on ARIUS Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARIUS Research.

Explore the full profile